Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics
Professor Erik Stroes gives an overview of evidence that inflammation plays a role in CKD and diabetes and considers options to target the hyperactive inflammatory state to lower residual CV risk.
Video navigation menu
- Is there an end to LDL-c lowering mediated risk reduction? 00:51
- Relevance of inflammation in chronic kidney disease 06:08
- Relevance of inflammation in diabetes mellitus type II 08:14
- Inflammation as therapeutic target: the CANTOS trial 09:34
- The role of epigenetics in developing anti-inflammatory interventions 11:32
This lecture was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy? held at ERA-EDTA in Copenhagen, Denmark.
Prof. Erik Stroes, MD - Professor of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.